Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 25

recruiting
3 973
countries
28
conditions
2 104

1 112 trials match your criteria

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Crohn's disease

Recruiting

Study of Mirikizumab for Children with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Mirikizumab

Osteoarthritis

Recruiting

Study on Shortened Anticoagulation with Rivaroxaban for Blood Clot Prevention in Patients Undergoing Hip Replacement Surgery

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban

Non-small cell lung cancer+1

Recruiting

Long-Term Safety Study of Dabrafenib Mesylate and Trametinib Dimethyl Sulfoxide for Patients Benefiting from Previous Treatment in Multiple Indications

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dabrafenib Mesylate

Acquired antithrombin III deficiency+1

Recruiting

Study on Antithrombin III Human for Patients with Heparin Resistance Undergoing Cardiac Surgery with Cardiopulmonary Bypass

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride

Neovascular age-related macular degeneration

Recruiting

Study on Long-Term Safety of Ranibizumab for Patients with Wet Age-Related Macular Degeneration Using a Port Delivery System

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Ranibizumab

Squamous cell carcinoma of skin

Recruiting

Study of Nivolumab and Nivolumab Plus Relatlimab for Patients with Advanced or Metastatic Skin Squamous Cell Carcinoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Nivolumab

Squamous cell carcinoma of lung

Recruiting

Study of Pembrolizumab and MK-2870 for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Acute lymphocytic leukaemia

Recruiting

Study Comparing Inotuzumab Ozogamicin to Drug Combination for Children with High-Risk Relapsed B-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Crisantaspase

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Guselkumab for Children with Moderate to Severe Crohn's Disease

Investigational
Countries:AustriaAustria
  • Participants:0–17 years
  • Substances:Guselkumab

Diffuse large B-cell lymphoma

Recruiting

Study on High-Dose Chemotherapy with Cytarabine and Drug Combination for Elderly Patients with Primary CNS Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:65+ years
  • Substances:Busulfan

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.